2026-09-19T09:29:56Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/335552021-07-05T14:03:20Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Edward B. Roberts, Robert S. Langer and Mriganka Sur.
Dutt, Anindita, 1971-
Management of Technology Program.
Management of Technology Program.
Sloan School of Management
2006-07-31T15:12:12Z
2006-07-31T15:12:12Z
2005
2005
http://hdl.handle.net/1721.1/33555
63272900
Thesis (S.M.M.O.T.)--Massachusetts Institute of Technology, Sloan School of Management, Management of Technology Program, 2005.
Includes bibliographical references (leaves 108-122).
NeuroBioChip Device is a programmable, biocompatible, biodegradable, polymer matrix which allows the growth and programming of donor neurons. It creates a microenvironment conducive for neuronal outgrowth and promises a novel cure for neurological disorders caused by localized sites of brain damage, such as Parkinson's disease, stroke, and spinal injury. This chip is being researched in the MIT laboratories of Drs. Robert Langer and Mriganka Sur. My thesis addresses the challenges and possible strategies in commercializing this technology. The need for this treatment was evaluated in the context of current therapies available for the treatment of relevant neurological disorders. Extensive field interviews were conducted. Among other factors, the varying clockspeeds between different components of the device, the unsustainable cost structure and the emerging status of complementary technologies suggested that the development of the therapy is best pursued in collaboration with a large biopharmaceutical or medical device firm.
by Anindita Dutt.
S.M.M.O.T.
122 leaves
7264217 bytes
7269314 bytes
application/pdf
application/pdf
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
Management of Technology Program.
The potential commercialization of neuronal replacement therapy using smart polymers
Thesis
application/pdf
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="62db0553-200b-496f-bf5c-7bc5c296c811">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>The potential commercialization of neuronal replacement therapy using smart polymers</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2005</PublicationDate>
<Authors>
<Author>
<DisplayName>Dutt, Anindita, 1971-</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Management of Technology Program.</Keyword>
<Abstract>NeuroBioChip Device is a programmable, biocompatible, biodegradable, polymer matrix which allows the growth and programming of donor neurons. It creates a microenvironment conducive for neuronal outgrowth and promises a novel cure for neurological disorders caused by localized sites of brain damage, such as Parkinson's disease, stroke, and spinal injury. This chip is being researched in the MIT laboratories of Drs. Robert Langer and Mriganka Sur. My thesis addresses the challenges and possible strategies in commercializing this technology. The need for this treatment was evaluated in the context of current therapies available for the treatment of relevant neurological disorders. Extensive field interviews were conducted. Among other factors, the varying clockspeeds between different components of the device, the unsustainable cost structure and the emerging status of complementary technologies suggested that the development of the therapy is best pursued in collaboration with a large biopharmaceutical or medical device firm.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>